Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/76098
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: "Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again?
Author: Price, T.
Townsend, A.
Beeke, C.
Bishnoi, S.
Padbury, R.
Maddern, G.
Karapetis, C.
Citation: Asia Pacific Journal of Clinical Oncology, 2012; 8(1):10-13
Publisher: Blackwell Publishing Ltd.
Issue Date: 2012
ISSN: 1743-7555
1743-7563
Statement of
Responsibility: 
Timothy J. Price, Amanda R. Townsend, Carol Beeke, Sarwan Bishnoi, Robert Padbury, Guy Maddern and Christos S. Karapetis
Abstract: AIM: The role of chemotherapy in metastatic colorectal cancer (mCRC) is firmly established and the option of watchful waiting (WW) has become an alternative rarely considered. However, there may be a group of patients who are diagnosed with low volume and asymptomatic disease and who may be suitable for a WW plan. METHODS: From the South Australian Cancer Registry for mCRC we examined cancer characteristics and outcomes of patients who were suitable for chemotherapy but had their treatment delayed by more than 3 months from diagnosis of metastatic disease. RESULTS: Data from 417 mCRC patients who received chemotherapy as first intervention have been entered in the Registry to date and 38 (9.1%) had chemotherapy commencement delayed by more than 3 months from diagnosis. Their median age was 76.7 years (range 38–85). Overall 87% of patients had metachronous metastatic cancer with a median time to recurrence of 2.1 years (range 0.53–7.71) and 65.5% had single organ metastasis. Median delay from the diagnosis of metastatic disease to chemotherapy was 5.03 months (range 3–28). The median survival has yet to be reached. The 2-year overall survival is 65%. CONCLUSION: We found that almost 10% of all patients with mCRC had a delay in the initiation of chemotherapy, with most due to a WW approach based on case note review. Patients with a delay in chemotherapy initiation are more likely to have a single organ site of metastatic disease and are older than those who do not. Despite the treatment delay, there is no evidence of a negative impact on survival.
Keywords: Chemotherapy
colorectal
survival
watchful waiting
Rights: © 2012 Blackwell Publishing Asia Pty Ltd.
DOI: 10.1111/j.1743-7563.2011.01458.x
Published version: http://dx.doi.org/10.1111/j.1743-7563.2011.01458.x
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.